Canadian Sec - Delayed Quote CAD

METheraHld (METX.CN)

8.00

0.00

(0.00%)

At close: January 30 at 3:35:05 PM EST

ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo

Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that its first therapeutic mRNA candidate from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics") has demonstrated encouraging anti-cancer activity in a mouse model o

Newsfile 17 days ago

METXF
ME Therapeutics Holdings Inc. Appoints Chief Business Officer

Vancouver, British Columbia--(Newsfile Corp. - October 25, 2024) - ME Therapeutics Holdings Inc. (CSE:METX) (FSE:Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce the appointment of Karim Lalji as Chief Business Officer. "We are excited to be able to announce the addition of Karim Lalji as Chief Business Officer," said Salim Dhanji, PhD, Chief Executive Officer of ...

Newsfile 3 months ago

METXF
ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to update investors on the progress of our research and development and corporate development plans. G-CSF Antibody Candidate UpdateThe Company is continuing to advance our lead anti-G-CSF antibody candidate, h1B11-12

Newsfile 3 months ago

METXF
ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). As previously disclosed, ME Therapeutics a

Newsfile 4 months ago

METXF
ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce a strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). This partnership aims to test the delivery and efficacy of mRNA-based drug candidates targeted to myeloid cells.ME Thera

Newsfile 6 months ago

METX.CN
0.00%
Q9T.F
ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company has engaged two new clinical consultants to help advance our lead anti-G-CSF antibody candidate (h1B11-12) towards a first in-human clinical trial.Dr. Kate Hanham, PhD, is a clinical trial con

Newsfile 7 months ago

METX.CN
0.00%
Q9T.F
ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities

Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company will be presenting at the Investor Clubhouse during the RBC Canadian Open PGA golf tournament presented by Investor.Events. ME Therapeutics will be presenting on Friday, May 31st, 2024, provid

Newsfile 8 months ago

METX.CN
0.00%
Q9T.F
ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024

Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company's management will be ringing the opening bell for the Canadian Securities Exchange on Wednesday April 17, 2024, and invites its shareholders to tune in at 930am EST to participate in the celebration. "We are ...

Newsfile 9 months ago

METX.CN
0.00%
Q9T.F
ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV

Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company's CEO, Dr. Salim Dhanji, will attend and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled to take place at the Metro Toronto Convention Centre in Toronto from ...

Newsfile 10 months ago

METX.CN
0.00%
Q9T.F
ME Therapeutics Announces Closing of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, announces the closing of its previously announced non-brokered private placement financing (the "Offering") and has issued 1,555,000 units (each, a "Unit") at a price of $1.00 per Unit raising gross proceeds of $1,555,000. Each Uni

Newsfile 10 months ago

METXF
ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - February 27, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce a non-brokered private placement financing to raise gross proceeds of up to $1,550,000 (the "Offering") and to provide an update on the status of its current research and development programs.The Offering

Newsfile 10 months ago

METX.CN
0.00%
Q9T.F

Performance Overview

Return	METX.CN	S&P/TSX Composite index
YTD	+100.00%	+3.71%
1-Year	+627.27%	+20.28%
3-Year	+15,900.00%	+23.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

METheraHld (METX.CN)

ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo

ME Therapeutics Holdings Inc. Appoints Chief Business Officer

ME Therapeutics Holdings Inc. Provides Research and Development Update and Corporate Update

ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration

ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells

ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial

ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities

ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024

ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV

ME Therapeutics Announces Closing of Non-Brokered Private Placement

ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update

Performance Overview